The addition of Versamune HPV (PDS0101) to pembrolizumab demonstrated robust and durable responses in first-line treatment for HPV16-positive recurrent or metastatic HNSCC.
PDS Biotechnology's IMMUNOCERV trial shows an 84.4% overall survival rate at 36 months for advanced cervical cancer patients treated with PDS0101 and chemoradiation.